Adrenomed Treads A New Path In Septic Shock
German firm Adrenomed has received new funding to push its innovative antibody for septic shock further into development. The company talks to Scrip about how it works, and why it won’t allow the asset to be a victim of strategic decision making.
You may also be interested in...
The clinical trial that caused Eli Lilly abruptly to withdraw its septic shock treatment Xigris (drotrecogin alfa [activated]) from all markets in October 2011 (scripintelligence.com, 27 October 2011) may have been flawed, or at least atypical of clinical practice, according to a recent meta-analysis of Xigris studies.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.